Editor’ summary: A paradigm shift in castration-resistant prostate cancer management

Editor’ summary: A paradigm shift in castration-resistant prostate cancer management
复制标题

编辑摘要:去势抵抗性前列腺癌治疗的范式转变

DOI:
10.1038/s41391-022-00574-x
复制
发表时间:
2022
影响因子:
4.8
通讯作者:
T. Dorff
T. Dorff
中科院分区:
医学2区
文献类型:
--
作者:
C. de Nunzio;Andrew J Amstrong;I. V. van Oort;T. Dorff

文献摘要

参考文献

被引文献

相似文献

前列腺癌(PCa)是西方国家最常见的老年男性非皮肤癌,尽管有几种手术和非手术治疗方案,但不幸的是,所有患者中有10%-20%将在确诊后5年内发展为去势抵抗状态(CRPC)[1,2]。直到2010年,雄激素剥夺疗法和多西紫杉醇是治疗转移性CRPC患者的唯一有效策略[1,2]。之后,几种激素和非激素疗法,如阿比特龙、阿帕鲁胺、卡巴紫杉醇、苯扎鲁胺、达鲁他胺、免疫治疗药物siPuleucel-T、用于部分同种修复缺陷男性的PARP抑制剂olaparib,以及放射性药物镭-223,在显示出对转移性或非转移性CRPC(MCRPC)患者的显著生存益处后,被批准[2]。尽管有所有这些治疗选择,许多问题仍然没有得到解决。在这个在线文集(https://www.nature.com/pcan/collections),)中,PCAN的编辑精选了过去几年在我们杂志上发表的十篇关键论文,这些论文突出了CRPC管理中的重要临床和翻译进展,并提供了新的见解。特别是审议了三个专题。
Prostate cancer (PCa) is the most common non-skin cancer in elderly males in Western countries and despite several surgical and non-surgical therapeutic options, unfortunately, 10–20% of all patients will develop a castration-resistant status (CRPC) within 5 years from diagnosis [1, 2]. Until 2010, androgen deprivation therapy and docetaxel were the only available strategies to manage patients with metastatic CRPC [1, 2]. Afterwards, several hormonal and non-hormonal treatments such as abiraterone acetate, apalutamide, cabazitaxel, enzalutamide, darolutamide, the immunotherapeutic sipuleucel-T, the PARP inhibitor olaparib for selected men with homologous repair deficiencies, and the radiopharmaceutical radium-223, were approved after showing a significant survival benefit in patients with metastatic or nonmetastatic CRPC (mCRPC) [2]. Notwithstanding all these therapeutic options, many questions remain unsolved. In this online collection (https://www.nature.com/pcan/collections), the editors of PCAN have selected ten key papers, published in the last years on our journal, which highlight and provide novel insights into important clinical and translational advances in the management of CRPC. Particularly three topics have been considered.
DOI: 10.1200/jco.2017.77.6880
发表时间: 2018-08-20
影响因子: 45.3
作者:
Aggarwal, Rahul;Huang, Jiaoti;Small, Eric J.
通讯作者: Small, Eric J.